Selank reverses genetically-based depression symptoms in WAG/Rij rats at high repeated doses
Background
Depression remains difficult to model reliably in rodents, with standard forced-swimming paradigms often criticized for low translational validity and susceptibility to confounds from locomotor changes. Genetically-based depressive behavior in inbred WAG/Rij rats — characterized by increased immobility and anhedonia (reduced sucrose preference) — offers a proposed alternative with higher construct validity. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide derived from the endogenous immunomodulatory peptide tuftsin, already established as a selective anxiolytic that completed Phase III clinical trials. Its neurobiochemical profile activates brain monoaminergic systems, stimulates dopamine synthesis and turnover, and modulates tyrosine hydroxylase activity — a mechanistic fingerprint overlapping both antidepressants and psychostimulants — making it a rational candidate for antidepressant investigation.
Study Design
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) was administered to three rodent groups: inbred WAG/Rij rats (inherited depression model), outbred Wistar rats (control), and BALB/c mice (situation-provoked depression model). In WAG/Rij rats, high doses of 1000–2000 µg/kg were given via repeated injection; in BALB/c mice, low doses of 100 and 300 µg/kg were tested after single injection, and high doses of 600 and 900 µg/kg after repeated injection. Primary endpoints were immobility duration in the forced swimming test, sucrose intake/preference as an anhedonia index, and general locomotor activity and anxiety measures.
Results
In WAG/Rij rats, repeated administration of selank at 1000–2000 µg/kg counteracted both hallmark depression symptoms: it reduced increased immobility in the forced swimming test and reversed decreased sucrose intake/preference (anhedonia). In BALB/c mice, single injection at 100 and 300 µg/kg significantly reduced immobility duration in the forced swimming test, demonstrating a clear antidepressant signal at low doses. However, repeated injection in BALB/c mice did not produce a significant antidepressant effect, and high doses of 600–900 µg/kg in these mice also failed to exert a significant effect — suggesting a dose-response inversion or tolerance phenomenon in the situation-provoked model.
The most striking result: selank's antidepressant effect in the genetically-based WAG/Rij model required repeated high-dose administration, while single low-dose injection sufficed in the situation-provoked BALB/c model — highlighting model-dependent pharmacodynamics.
Selank did not affect general locomotor activity or anxiety levels in WAG/Rij rats, and produced no substantial behavioral change in control Wistar rats, supporting specificity of the antidepressant effect rather than nonspecific stimulation.
Key Findings
- Selank at 1000–2000 µg/kg (repeated) reduced immobility and reversed anhedonia in WAG/Rij rats
- Single injection of 100–300 µg/kg selank decreased immobility duration in BALB/c mice
- Repeated injection or high doses (600–900 µg/kg) failed to show effect in BALB/c mice
- Selank did not alter locomotor activity or anxiety in WAG/Rij rats, indicating specificity
- WAG/Rij model judged more reliable than standard forced swimming test for antidepressant screening
Why It Matters
Selank's antidepressant component adds a clinically meaningful dimension to its established anxiolytic profile — clinicians and peptide users evaluating it purely as an anxiolytic may be underestimating its mood-regulatory potential. The dose-dependency is critical for protocol design: low single doses (100–300 µg/kg equivalent) appear effective for acute situational depression, whereas chronic genetically-driven depressive phenotypes may require higher repeated dosing. The absence of locomotor or anxiety confounds strengthens confidence that observed antidepressant effects are genuine. However, selank is still an animal-data story for this indication; its Phase III completion was for anxiolytic use, so antidepressant clinical translation remains a separate, uncharted regulatory pathway. Stack-minded users should note that combining selank's monoaminergic and dopaminergic activation with existing antidepressants warrants caution until interaction data exist.
TitrateLab articles covering Selank
Written by TitrateLab, separately from the study summarized above.
